Business
NRx Pharmaceuticals (NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical
LOS ANGELES, CA - September 9, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has closed the acquisition of Dura Medical, a reven...
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"LOS ANGELES, CA - September 9, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has closed the acquisition of Dura Medical, a revenue-generating and EBITDA-positive provider of interventional psychiatry services in Naples and Ft. Myers, Florida. Dura, founded in 2018, delivers treatments for depression, PTSD, suicidality, anxiety, and chronic pain through Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, Spravato(R), Stellate Ganglion Blocks, and traditional psychiatry. The acquisition, along with pending deals for Neurospa TMS and Cohen and Associates, expands HOPE's planned network to more than eight locations across Florida. Stephen Durand, Dura's founder and a U.S. Army veteran, has been appointed Director of Florida Clinic Operations.","length":888,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":610,"height":520,"url":"https://media.zenfs.com/en/newsmediawire_165/d8af5ae9288c0f70ceb08aa9713a28cf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kpD0NvVnaK_aNpdu.cQQ2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTgxODtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/d8af5ae9288c0f70ceb08aa9713a28cf","width":610,"height":520}}},{"type":"text","content":"To view the full press release, visit https://ibn.fm/RSnyG","length":58,"tagName":"p"},{"type":"text","content":"About NRx Pharmaceuticals, Inc.","length":31,"tagName":"p"},{"type":"text","content":"NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Appli...